I’m a Pathologist. The Ozempic & Mounjaro Cost You Can’t Feel Yet.

Main ideas, concepts, and lessons

• The speaker addresses a common patient concern about GLP-1–based weight loss/diabetes drugs (e.g., Ozempic, Mounjaro, Wegovy, Zepbound)—specifically: “what are these drugs doing to me that I can’t feel yet?”
• The video frames itself as an evidence-based safety review, drawing on:
  • long-term trials,
  • the FDA label, and
  • newer safety studies.
• Key framing: instead of only asking “is it safe or dangerous,” the speaker says the better question is the one patients keep asking—“what might it do over years that I can’t feel yet?”
• Safety is organized into five “files”, each with a verdict:
  • Cancer
  • Gut/kidneys
  • Eyes
  • Muscle
  • Brain/mood
• Each category gets one of four verdicts: reassuring, uncommon, emerging, or still unknown.
• Overall conclusion emphasized:
  • evidence is more reassuring than internet headlines, but
  • there are no 10–20 year data for today’s higher-dose obesity regimens.

---

Drug family background (what the video says these drugs are)

• Semaglutide
  • Described as: semaglutide (OMPC/“Wegovy” and Ozempic)
• Tirzepatide
  • Described as: tirzepatide (Mounjaro and Zepbound)
• These drugs mimic gut hormones:
  • GLP-1 (released after meals; affects insulin release and fullness)
  • GIP (also mimicked by tirzepatide; described as a “second gut hormone”)
• Timeline described:
  • GLP-1 family origin drugs approved starting 2005
  • semaglutide in 2017
  • tirzepatide in 2022
• The speaker notes that high-dose weight-loss use is relatively new (about ~5 years), calling it a “double-edged sword.”

---

File-by-file safety review (evidence + what it means)

1) Cancer

Claimed FDA concern / origin

• The FDA “black box” warning is linked to rodent thyroid C-cell tumors (medullary thyroid cancer) seen during development.
• The speaker emphasizes:
  • in rodents, C-cells have more GLP-1 receptors (drug docking sites),
  • in humans, C-cells have far fewer, making rodent findings uncertain for human risk.
• Stated verdict: “reassuring but not closed”
  • no convincing human increase in larger studies,
  • but not definitively “proven absent.”

Human evidence cited

• 2023 French study (national insurance database)
  • ~58% higher thyroid cancer diagnosis rate with GLP-1 use for 1–3 years
• 2024 Scandinavian study
  • followed 145,000 GLP-1 users for ~3.9 years
  • no meaningful increase, though a small increase could not be ruled out
• 2025 study
  • pooled six national databases
  • no increase found
• 2026 analysis of 93 trials
  • no link reported
  • noted as authored by scientists from Novo Nordisk (manufacturer of semaglutide)

Why studies might disagree

• The speaker suggests detection bias:
  • after a thyroid warning, clinicians may order more neck ultrasounds
  • ultrasounds may find nodules that existed before
  • some get biopsied and labeled as cancer, increasing diagnoses without changing true incidence

Pancreatic cancer

• Addresses concern about pancreatic cancer using:
  • a large observational study of 1.65 million Americans with type 2 diabetes followed up to 15 years
    • no increased pancreatic cancer signal
    • rates were lower than in people on insulin
    • benefits didn’t persist when compared to metformin
      • speaker uses this to avoid claiming prevention
• Verdict: no pancreatic cancer signal so far (presented as reassuring, not proven preventive effect)

Who should treat this as a “hard stop”

• If someone has a family history or personal condition of:
  • medullary thyroid cancer, or
  • MEN2 (multiple endocrine neoplasia type 2)
• They should tell their prescriber before refills.

---

2) Gut + kidneys (and gallbladder)

Core mechanism

• These drugs slow stomach emptying, contributing to:
  • fullness,
  • nausea,
  • and rarely, gastroparesis

Pancreatitis / bowel obstruction / gastroparesis

• Spark for attention:
  • 2023 observational study in JAMA
    • higher rates of pancreatitis, bowel obstruction, and gastroparesis vs another weight-loss drug
    • reported “about nine-fold” pancreatitis increase
• Speaker’s interpretation of the “nine-fold” number:
  • compared semaglutide to liraglutide (“older cousin”)
  • comparison group had only 1 pancreatitis case, making the ratio unstable
  • uncertainty described as extremely wide (“barely higher to 66 times higher”)
• Semaglutide-specific figures cited:
  • 613 people followed median 7 months
  • 2 pancreatitis cases and 0 bowel obstruction
• A major semaglutide trial referenced:
  • pancreatitis was not higher than placebo

Verdict framing for emergencies

• Risks treated as documented and uncommon, but important to recognize early.

Gallbladder issues

• Described as more settled:
  • rapid weight loss can increase cholesterol in bile → gallstones risk
• Evidence cited:
  • 2022 analysis of 76 trials, 100,000+ people
    • ~37% increased gallbladder problems overall
    • more than doubled in weight-loss trials
• Risk increases with:
  • higher doses and longer use
• Noted as already included “on the label” “for years.”

Kidney risk

• Concern: these drugs could damage kidneys
• Speaker’s counterpoint:
  • in type 2 diabetes with chronic kidney disease, semaglutide may protect kidneys
  • 2024 trial:
    • 3,500+ people
    • 24% fewer major kidney events over 3.4 years
• Label danger (indirect):
  • vomiting → dehydration → kidney injury

Hydration recommendation (practical prevention)

• Speaker emphasizes hydration:
  • people may forget to drink when appetite is suppressed
  • if vomiting lasts for days, dehydration is the key mechanism

Anesthesia/surgery concern (aspiration risk)

• Because stomach empties slowly:
  • under general anesthesia with a full stomach, there may be risk of breathing stomach contents into lungs
• The label warns about this.
• The speaker notes surgeries are often rescheduled when patients arrive without following instructions.

What to do about this file (detailed instructions)

• Before surgery or colonoscopy
  • Tell the anesthesia team you are on one of these drugs.
  • Say it aloud, not only on forms.
• Emergency symptoms
  • Sudden severe upper belly pain that goes through to the back with vomiting → emergency visit
• If vomiting persists
  • If you can’t keep fluids down for more than a day, call the prescriber that day
• If you also use insulin or sulfonylureas
  • Ask whether doses should be reduced (risk of low blood sugar)
• Hydration
  • Maintain hydration and prevent vomiting-related dehydration

---

3) Eyes

The speaker says this file has two parts.

A) Older risk: diabetic retinopathy complications (semaglutide)

• 2016 trial (~3,300 people with type 2 diabetes)
  • semaglutide increased diabetic retinopathy complications
  • ~3% on drug vs ~1.8% on placebo
  • most affected patients already had eye disease
• Proposed mechanism:
  • fast blood sugar drops can worsen existing retinopathy
• Actions recommended:
  • for people with diabetes—especially with existing retinopathy or those expecting rapid A1C reduction:
    • ensure retinal screening is up to date
    • tell the eye doctor you’re initiating treatment
  • if vision changes occur, notify the doctor immediately

B) Newer risk: NAION (nonarteritic anterior ischemic optic neuropathy)

• More associated with semaglutide
• 2024 observation from Harvard’s eye hospital:
  • NAION cases in people on semaglutide
  • NAION described as:
    • impaired blood supply to the optic nerve
    • often overnight
    • waking with painless vision loss in one eye
    • frequently permanent
• Evidence cited:
  • ~4x risk in people with diabetes
  • ~7x risk in people using it for weight
  • small case counts noted (examples given such as 17 vs 6 and 20 vs 3)
• Later confirmation:
  • 2026 meta-analysis
    • combined eight population studies
    • nearly 6 million people
    • ~double risk overall
    • diabetes subgroup retained signal
    • weight-loss subgroup not statistically significant but pointed the same direction
• Regulators:
  • Europe added it to the label (speaker says)
  • FDA (as of Sept 6, 2026) had not yet added it to the US label at time of claim (with possible later change)

Verdict

• Emerging but serious, because rare events can be missed early—but once millions are exposed, signals appear—and the outcome can be permanent.

What to do (detailed instructions)

• If you ever wake with:
  • sudden vision loss, or
  • a dark patch in one eye
  • → same-day eye emergency
• If you have had NAION in one eye:
  • consider the other eye at risk
  • discuss risk with prescriber and ophthalmologist before starting any weight-loss medication

---

4) Muscle + face

Main claim

• Weight loss (by any method) can reduce muscle mass because you lose lean tissue alongside fat.

Semaglutide-related concern

• Speaker says there is no good evidence that semaglutide/tirzepatide selectively attacks muscle.

Face fat

• Fast facial fat loss can make the face look affected (“Ozempic face” framing).
• Reasoning:
  • facial fat pads shrink
  • skin may not shrink as quickly
• Speaker again: no good evidence of direct skin toxicity.

What to do (detailed instructions)

• To protect muscle (presented as supported by published data):
  • Enough protein
    • typical obesity-medicine range stated: 1.2–1.6 g/kg/day
    • speaker advises asking the physician, especially if:
      • kidney issues
      • chronic illnesses/comorbidities
  • Resistance training
    • lifting something heavy twice a week
  • personalize intensity and safety with a physician

---

5) Brain + mood

Suicide / serious self-harm risk

• European reports in 2023 triggered regulatory investigation.
• Speaker’s summary of results:
  • big semaglutide trial:
    • serious suicide/self-injury events 0.11% in both groups
  • 2024 Nature Medicine study (~240,000 people with obesity):
    • suicidal thoughts were lower on semaglutide vs other weight-loss drugs
  • Jan 2026 pooling:
    • 91 trials + database over 2 million people
    • FDA found no increased risk
    • asked companies to remove warning from weight-loss labels

Anhedonia / decreased reward

• Caveat:
  • some patients report food becomes less rewarding or other things feel less rewarding (anhedonia)
• Speaker: depression/anhedonia deserves evaluation, but evidence is not yet strong on:
  • how common it is, or
  • whether the drug causes it

What to do (detailed instruction)

• Watch for mood changes lasting more than 2 weeks after starting or increasing dose:
  • tell the prescriber promptly for evaluation
  • don’t minimize symptoms—get assessed

---

Overall conclusions emphasized in the video

• No 10-year data on today’s high-dose obesity regimens.
• Longest randomized safety follow-up described:
  • semaglutide trial: ~3 years 4 months
  • tirzepatide randomized data: up to 176 weeks (~a bit over 3 years)
• Weight regain after stopping is common; obesity is treated as a chronic disease.
• Speaker says they will update if:
  • thyroid follow-up becomes longer
  • eye-signal evidence strengthens via independent trials

---

Special pregnancy / birth control instructions (detailed)

The speaker highlights birth-control issues “most people haven’t been told.”

If using semaglutide (Ozempic/Wegovy)

• Stop at least 2 months before trying to get pregnant
• Rationale: it takes about that long to clear from the body.

If using tirzepatide (Mounjaro/Zepbound)

Two issues are described:

1. The speaker implies a different risk mechanism related to stomach emptying affecting pill absorption.
2. Birth-control effectiveness guidance (pill specifically):
   • because slowed gastric emptying can reduce absorption of oral contraceptive pills, labels advise:
     • use barrier methods (e.g., condoms) or
     • switch to non-pill methods (IUD, implant, patch, ring, shot)
   • apply for:
     • the first 4 weeks after starting, and
     • 4 weeks after every dose increase
   • non-pill hormonal methods are said to be not affected

Additional instruction

• Read the package insert that comes with the pen and save the video for reference.

---

Speaker / source list (as featured in the subtitles)

Speaker

• Unnamed narrator
  • described as: a pathologist with obesity medicine training
  • independent medical educator
  • creator of the video and “GLP-1 method” program

Named external entities / sources (studies, regulators, institutions, drug makers)

• FDA
  • labeling; asked companies to remove warnings
  • NAION labeling status as of the date stated
• Novo Nordisk
  • noted as authoring at least one 2026 analysis
  • manufacturer of semaglutide
• JAMA
  • 2023 observational study on gut-related signals
• Harvard’s eye hospital
  • 2024 NAION observation
• Nature Medicine
  • 2024 study pooling obesity populations for suicide-related outcomes
• South Korea
  • detection-bias example from the 2000s
• European drug regulator
  • added NAION to label
• Additional studies/databases referenced (without specific author names):
  • 2023 French national insurance database thyroid study
  • 2024 Scandinavian study (145,000 users)
  • 2025 pooled six national databases thyroid study
  • 2026 analysis of 93 trials (thyroid)
  • 2024 kidney trial (3,500+ people; kidney protection claim)
  • 2026 meta-analysis of NAION (eight population studies; ~6 million people)
  • semaglutide diabetes retinopathy trial (2016; ~3,300 people)
  • semaglutide/safety pooling in Jan 2026 (91 trials; 2+ million database)
  • 2024 tirzepatide stopping/switch trial (weight regain data)

Drugs mentioned

• Semaglutide: Ozempic, Wegovy
• Tirzepatide: Mounjaro, Zepbound
• “Zepbound” / “Zipbound” spelling appears in subtitles
• Comparator mentioned:
  • liraglutide
• Other diabetes meds mentioned:
  • metformin, insulin, sulfonylurea (subtitle: “sulonyl ura”)
• Targets:
  • GLP-1 and GIP (hormonal targets)